Retinal Neuroprotective Effects of Flibanserin, an FDA-Approved Dual Serotonin Receptor Agonist-Antagonist.
Aaron S CoynerRenee C RyalsCristy A KuCody M FischerRachel C PatelShreya DattaPaul YangYuquan WenRené HenMark E PennesiPublished in: PloS one (2016)
Intraperitoneal delivery of flibanserin in a light-induced retinopathy mouse model provides retinal neuroprotection. Mechanistic data suggests that this effect is mediated through 5-HT1A receptors and that flibanserin augments the expression of genes capable of reducing mitochondrial dysfunction and oxidative stress. Since flibanserin is already FDA-approved for other indications, the potential to repurpose this drug for treating retinal degenerations merits further investigation.
Keyphrases
- optical coherence tomography
- diabetic retinopathy
- oxidative stress
- mouse model
- optic nerve
- poor prognosis
- drug administration
- electronic health record
- genome wide
- dna damage
- brain injury
- emergency department
- big data
- ischemia reperfusion injury
- gene expression
- machine learning
- blood brain barrier
- induced apoptosis
- genome wide identification
- drug induced
- signaling pathway
- heat shock protein